COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00200694
Recruitment Status : Terminated (difficulty in patients's inclusion)
First Posted : September 20, 2005
Last Update Posted : February 4, 2009
Information provided by:
Nantes University Hospital

Brief Summary:
Determine the best strategy for proteinuria lowering in patients with proteinuria > 1 g/day receiving ACEI and ARB combination: either increase of ACEI and ARB dosage or increase of diuretic dosage.

Condition or disease Intervention/treatment Phase
Heavy Proteinuria Drug: ramipril 5 mg + valsartan 80 mg/day, Drug: ramipril 10 mg + valsartan 160 mg/day, Drug: ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide. Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Study Start Date : March 2005
Actual Primary Completion Date : March 2007
Actual Study Completion Date : March 2007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • proteinuria > 1 g/day with ramipril 5 + valsartan 80 mg/day for 2 months
  • proteinuria changes < 50% on 3 separate dosages over 2 months.

Exclusion criteria:

  • age < 18 or > 80 years systolic BP < 110 or ≥ 140 mmHg, serum creatinine > 250 mmole/L
  • serum creatinine increase on ramipril + valsartan > 20%
  • intolerance to ACEI or ARB

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00200694

Layout table for location information
CHU de Nantes
Nantes, France
Sponsors and Collaborators
Nantes University Hospital
Layout table for investigator information
Principal Investigator: Vincent LM Esnault, MD PHD CHU de Nantes
Layout table for additonal information Identifier: NCT00200694    
Other Study ID Numbers: BRD 03-5-D
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: February 4, 2009
Last Verified: February 2009
Keywords provided by Nantes University Hospital:
blood pressure
renal failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Urination Disorders
Urologic Diseases
Urological Manifestations
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors